Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
22h
LGBTQ Nation on MSNOnce-a-year shot for HIV protection passes early safety trialAn annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
A NEW injection that could prevent HIV infection has successfully completed an early safety trial, according to a report in ...
However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...
To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.
5h
Barchart on MSNGilead Sciences - Leader in HIV MedicinesYour FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and ...
In a ceremony held last month, the 2024 Louisa Gross Horwitz Prize was awarded to Wesley Sundquist, PhD, Leo T. and Barbara K ...
Blood donation is widely recognized as a life-saving act, replenishing hospital supplies and aiding patients. But could ...
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results